Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States

Journal of the National Cancer Institute

Volumn 108, Issue 7, 2016, Pages

  Padula, William V ^a   Larson, Richard A ^b   Dusetzina, Stacie B ^c   Apperley, Jane F ^d   Hehlmann, Rudiger ^e   Baccarani, Michele ^f   Eigendorff, Ekkehard ^h   Guilhot, Joelle ⁱ   Guilhot, Francois ⁱ   Mahon, Francois Xavier ^j   Martinelli, Giovanni ^g   Mayer, Jiri ^k   Müller, Martin C ^e   Niederwieser, Dietger ^l   Saussele, Susanne ^e   Schiffer, Charles A ^m   Silver, Richard T ⁿ   Simonsson, Bengt ^o   Conti, Rena M ^b,p  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c University of North Carolina   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h JENA UNIVERSITY HOSPITAL   (Germany)

ⁱ POITIERS UNIVERSITY HOSPITAL   (France)

^j UNIVERSITÉ DE BORDEAUX   (France)

^k UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^l UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^m WAYNE STATE UNIVERSITY   (United States)

ⁿ WEILL CORNELL MEDICAL CENTER   (United States)

^o UPPSALA UNIVERSITY   (Sweden)

^p NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; GENERIC DRUG; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PHYSICIAN; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UNITED STATES; ANTAGONISTS AND INHIBITORS; CLINICAL PRACTICE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; FEMALE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MARKOV CHAIN; MIDDLE AGED; MORTALITY; STANDARDS; STATISTICAL MODEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRENDS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUGS, GENERIC; FEMALE; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMETRIC; PRACTICE PATTERNS, PHYSICIANS'; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84979255197     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw003     Document Type: Article

References (52)

1. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
2. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
3. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423-1432.
4. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. ASH Annual Meeting Abstracts. 2009;114(22):1126.
5. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
6. Cortes J, Saglio G, Baccarani M, et al. Final Study Results of the Phase 3 Dasatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Trial (Dasision, CA180-056). ASH Annual Meeting Abstracts. 2014;124(21).
7. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.
8. Larson RA, Kim DW, Issaragrisil S, et al. Efficacy and Safety of Nilotinib vs. Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up of ENESTnd. ASH Annual Meeting Abstracts. 2014;124(21).
9. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-2259.
10. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439-4442.
11. Conti RM. Why are cancer drugs commonly the target of numerous schemes to extend patent exclusivity? Health Affairs Blog. December 4, 2013.
12. Kantarjian H, Steensma D, Rius Sanjuan J, et al. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014;10(4):e208-e211.
13. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158(2):84-92.
14. Conti RM, Berndt ER. Specialty drug prices and utilization after loss of US patent exclusivity, 2001-2007. In. NBER Working Paper Series 20016: National Bureau of Economic Research (NBER); 2014.
15. Generic Imatinib. http://cmlsociety.org/generic-tyrosine-kinase-inhibitorstkis- arrive-in-canada/. Accessed January 30, 2016.
16. Dunne S, Shannon B, Dunne C, et al. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol. 2013;14:1.
17. de Lemos ML, Kyritsis V. Clinical efficacy of generic imatinib. J Oncol Pharm Pract. 2015;21(1):76-79.
18. Gold M, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
19. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200-1206.
20. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353-1360.
21. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123(4):494-500.
22. Jabbour E, le Coutre PD, Cortes J, et al. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013;27(4):907-913.
23. Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123(15):2317-2324.
24. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112(12):4437-4444.
25. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758-3765.
26. Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118(17):4554-4560.
27. Williams LA, Garcia Gonzalez AG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013;122(5):641-647.
28. Szabo SM, Levy AR, Davis C, et al. A multinational study of health state preference values associated with chronic myelogenous leukemia. Value Health. 2010;13(1):103-111.
29. Innes AJ, Apperley JF. Chronic Myeloid Leukemia-Transplantation in the Tyrosine Kinase Era. Hematol Oncol Clin North Am. 2014;28(6):1037-1053.
30. Padula W, Allen R, Nair K. Determining the cost of obesity and its common comorbidities from a commercial claims database. Clin Obesity. 2014;4(1):53-58.
31. Guerin A, Chen L, Dea K, et al. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ. 2014;17(2):89-98.
32. Preussler JM, Denzen EM, Majhail NS. Costs and cost-effectiveness of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1620-1628.
33. Conti RM, Padula WV, Larson RA. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol. 2015; In Press.
34. Grabowski H, Vernon J. Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade. Pharmacoeconomics. 1996;10(Suppl 2):110-123.
35. Grabowski H, Vernon J. Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act. J Law Econ. 1992;35:331-350.
36. Reiffen D, Ward MR. Generic drug industry dynamics. Rev Econ Statistics. 2005;87(1):37-49.
37. Wiggins SN, Maness R. Price Competition in Pharmaceuticals: The Case of Anti'infectives. Econ Inquiry. 2004;42(2):247-263.
38. Motheral BR. Pharmaceutical step-therapy interventions: a critical review of the literature. J Manag Care Pharm. 2011;17(2):143-155.
39. Nayak RK, Pearson SD. The Ethics Of 'Fail First': Guidelines And Practical Scenarios For Step Therapy Coverage Policies. Health Affairs. 2014;33(10):1779-1785.
40. Pearson CF. Consumers face more hurdles to accessing drugs in exchange plans compared to employer coverage. Washington, DC: Avalere Health; March 2014.
41. Paradis PE, Latremouille-Viau D, Moore Y, et al. Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. Curr Med Res Opin. 2009;25(7):1793-1805.
42. 2013-2014 Prescription Drug Benefit Costs and Plan Design Report. In: Pharmacy Benefit Management Institute; August 2013; Plano, TX.
43. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14):3733-3736.
44. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-2388.
45. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401-5411.
46. Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306-311.
47. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
48. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424-430.
49. Delphine R, Nicolini F, Tulliez M, et al. Dasatinib or nilotinib discontinuation in chronic phase-chronic myeloid leukemia patients with durably undetectable BCR-ABL transcripts: Interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months - on Behalf of the French CML Group FILMC. ASH Annual Meeting Abstracts. 2014;124(21).
50. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515-522.
51. Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2014;20(2):310-322.
52. Mahon FX. Is going for cure in chronic myeloid leukemia possible and justifiable? Hematology Am Soc Hematol Educ Program. 2012;2012:122-128.